Emcure Pharma forms subsidiary to strengthen dermatology portfolio

The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore

USFDA inspection of Shilpa Medicare Unit VI at Bengaluru

The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature

MilliporeSigma invests US$ 76 million to expand ADC manufacturing in North America

Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America

MRP of anti-cancer drugs to come down due to custom duty exemption and GST rate reduction

This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty

Prime Minister launches expansion of health coverage for citizens of and above 70 years

Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age

Mankind Pharma completes acquisition of BSV

Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.

Lupin appoints Claus Jepsen as President, Global Specialty

JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24

JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%

Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules

Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension